MA39337A1 - Modulateurs de pyrazines de gpr6 - Google Patents

Modulateurs de pyrazines de gpr6

Info

Publication number
MA39337A1
MA39337A1 MA39337A MA39337A MA39337A1 MA 39337 A1 MA39337 A1 MA 39337A1 MA 39337 A MA39337 A MA 39337A MA 39337 A MA39337 A MA 39337A MA 39337 A1 MA39337 A1 MA 39337A1
Authority
MA
Morocco
Prior art keywords
gpr6
modulators
pyrazines
compounds
methods
Prior art date
Application number
MA39337A
Other languages
English (en)
Other versions
MA39337B1 (fr
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Huikai Sun
Shota Kikuchi
Maria Hopkins
Mark E Adams
Jason W Brown
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39337A1 publication Critical patent/MA39337A1/fr
Publication of MA39337B1 publication Critical patent/MA39337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) : qui sont utiles en tant que modulateurs de gpr6, des compositions pharmaceutiques de ceux-ci, des méthodes pour le traitement de conditions associées à gpr6, des procédés de fabrication de ces composés et des intermédiaires de ceux-ci.
MA39337A 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6 MA39337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Publications (2)

Publication Number Publication Date
MA39337A1 true MA39337A1 (fr) 2017-10-31
MA39337B1 MA39337B1 (fr) 2019-11-29

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39337A MA39337B1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (fr)
EP (1) EP3105216B1 (fr)
JP (1) JP6484640B2 (fr)
KR (1) KR20160122215A (fr)
CN (1) CN106103421B (fr)
AU (1) AU2015218402B2 (fr)
BR (1) BR112016018418A2 (fr)
CA (1) CA2939382A1 (fr)
CL (1) CL2016002043A1 (fr)
CR (1) CR20160428A (fr)
DO (1) DOP2016000211A (fr)
EA (1) EA033861B1 (fr)
EC (1) ECSP16074207A (fr)
ES (1) ES2702205T3 (fr)
GE (2) GEP20186893B (fr)
IL (1) IL247140B (fr)
MA (1) MA39337B1 (fr)
MX (1) MX369857B (fr)
MY (1) MY184366A (fr)
PE (1) PE20170245A1 (fr)
PH (1) PH12016501613B1 (fr)
UA (1) UA117779C2 (fr)
WO (1) WO2015123533A1 (fr)
ZA (1) ZA201606077B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170245A1 (es) * 2014-02-14 2017-03-30 Takeda Pharmaceuticals Co Pirazinas moduladoras de gpr 6
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
CN110520127B (zh) * 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
JP2023527961A (ja) * 2020-04-30 2023-07-03 オレゴン ヘルス アンド サイエンス ユニヴァーシティ ｇｐｒ３９タンパク質のアンタゴニスト

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
KR20030031886A (ko) 2000-02-16 2003-04-23 뉴로젠 코포레이션 치환된 아릴피라진
ATE448210T1 (de) * 2001-06-01 2009-11-15 Hoffmann La Roche Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
JPWO2004054617A1 (ja) * 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
RU2006105717A (ru) 2003-07-30 2007-09-20 Зинон Фармасьютиклз Инк. (Ca) Производные пиперазина и их применение в качестве терапевтических агентов
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
EP1742935B1 (fr) 2004-04-13 2010-02-24 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
WO2006124748A2 (fr) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Composes polycycliques et procedes pour les utiliser
WO2007044085A2 (fr) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
WO2011143495A1 (fr) 2010-05-13 2011-11-17 Amgen Inc. Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
AU2011253057B2 (en) * 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US10252984B2 (en) * 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
SI3060550T1 (sl) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilne spojine kot inhibitorji BTK in uporabe le-teh
PE20170245A1 (es) * 2014-02-14 2017-03-30 Takeda Pharmaceuticals Co Pirazinas moduladoras de gpr 6

Also Published As

Publication number Publication date
JP2017509601A (ja) 2017-04-06
GEP20186893B (en) 2018-09-10
ES2702205T3 (es) 2019-02-27
DOP2016000211A (es) 2016-10-16
WO2015123533A1 (fr) 2015-08-20
CL2016002043A1 (es) 2017-02-17
GEAP201814266A (en) 2018-05-10
US20180258073A1 (en) 2018-09-13
EP3105216B1 (fr) 2018-10-10
US10000468B2 (en) 2018-06-19
JP6484640B2 (ja) 2019-03-13
ECSP16074207A (es) 2017-09-29
IL247140B (en) 2020-02-27
US20170174659A1 (en) 2017-06-22
PE20170245A1 (es) 2017-03-30
MX369857B (es) 2019-11-25
UA117779C2 (uk) 2018-09-25
IL247140A0 (en) 2016-09-29
CA2939382A1 (fr) 2015-08-20
PH12016501613B1 (en) 2021-10-01
EA033861B1 (ru) 2019-12-03
MX2016010529A (es) 2016-10-31
CN106103421A (zh) 2016-11-09
EA201691632A1 (ru) 2017-02-28
MA39337B1 (fr) 2019-11-29
ZA201606077B (en) 2018-11-28
KR20160122215A (ko) 2016-10-21
BR112016018418A2 (pt) 2017-08-08
AU2015218402B2 (en) 2019-07-11
CN106103421B (zh) 2019-04-09
EP3105216A1 (fr) 2016-12-21
US10273225B2 (en) 2019-04-30
AU2015218402A1 (en) 2016-09-15
PH12016501613A1 (en) 2017-02-06
CR20160428A (es) 2017-04-04
MY184366A (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CO2017005218A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden los compuestos”
CO2017005452A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden tales compuestos
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201790806A1 (ru) Иммунорегулирующие средства
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
JOP20170169A1 (ar) مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
BR112016028255A2 (pt) agentes imunorreguladores
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
EA201691514A1 (ru) Соединения
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
JO3458B1 (ar) 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201790570A1 (ru) Модуляторы р2х7
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные